

High Potency Active Pharmaceutical Ingredients (HPAPI) Global Market – Forecast To 2023

<https://marketpublishers.com/r/H3CED6D8265EN.html>

Date: November 2017

Pages: 226

Price: US\$ 4,950.00 (Single User License)

ID: H3CED6D8265EN

Abstracts

The drugs are classified as High Potent if its Occupational Exposure Limit (OELs) ? 10µg/m³. The HPAPI global market is progressively increasing in terms of revenue and the rise in demand for outsourcing these intermediates, manufacturing is driven by expansion of oncology sector, which is the fastest among overall pharmaceutical sector.

The global HPAPI market is valued to be \$XX million in 2016 and poised to grow at a CAGR of X% to reach \$27,293.4 million by 2023. HPAPI market is mainly classified by customer base, by business type, by molecule type and Applications. The global HPAPI market is broadly classified as Innovative HPAPI and Generic HPAPI based on customer base. Based on business type, the market is classified into Captive HPAPI & Merchant HPAPI. HPAPI market is segmented on the basis of molecule type as Synthetic HPAPI and Biotech HPAPI. HPAPI market application segment is classified into Oncology, Cardiovascular, Central Nervous System, Hormonal, Glaucoma, Infectious, metabolic, Inflammation and other therapeutic applications.

Among Innovative & generic HPAPI, Innovative HPAPI occupies the major share in 2016 and generic HPAPIs expected to grow at a highest CAGR from 2016 to 2023. Among business type, Captive HPAPI occupies the major share of XX% in 2016 and Merchant HPAPI is expected to grow at a highest CAGR of X% from 2016 to 2023 to reach \$XX million by 2023. Among molecule type, Synthetic HPAPI occupies the major share in 2016 and is expected to grow at a CAGR of X% from 2016 to 2023 to reach \$XX million by 2023. Among Application segment, Oncology commanded the larger revenue of \$XX million in 2016 and is expected to grow at a highest CAGR of X% from 2016 to 2023.

Increasing incidence of chronic and age related diseases, rapid growth in oncology

market, growing demand for Antibody Drug Conjugates (ADC), technological advancements in HPAPI market, growing CMOs are some of the factors which are driving the market. Requirement of large investments, stringent safety and handling specifications associated with production of HPAPI, stringent regulations are the factors hindering the market.

North America accounts for the highest market share in 2016 and followed by Europe. However, Asian countries especially China and India are the fastest growing regions with its growing demand for HPAPIs. Asia-Pacific is projected to grow with a highest CAGR of XX% from 2016 to 2023.

Major players in HPAPI market include Alkermes plc (Ireland), Cambrex Corporation (U.S.), Dishman group (India), Dr. Reddy's Laboratories (India), Lonza Group (Switzerland), Novasep (U.S.), Patheon N.V. (Netherlands) (ThermoFisher Scientific), Pfizer (U.S.), Merck KGaA (Germany) and Teva Pharmaceutical Industries (Israel).

The report provides an in depth market analysis of the above mentioned segments across the following regions:

North America

Europe

Asia-Pacific

Rest of the World

Contents

1 EXECUTIVE SUMMARY

2 INTRODUCTION

2.1 KEY TAKE AWAYS

2.2 REPORT DESCRIPTION

2.3 MARKETS COVERED

2.4 STAKEHOLDERS

2.5 RESEARCH METHODOLOGY

2.5.1 MARKET SIZE ESTIMATION

2.5.2 MARKET BREAKDOWN AND DATA TRIANGULATION

2.5.3 SECONDARY SOURCES

2.5.4 PRIMARY SOURCES

2.5.5 KEY DATA POINTS FROM SECONDARY SOURCES

2.5.6 KEY DATA POINTS FROM PRIMARY SOURCES

2.5.7 ASSUMPTIONS

2.5.8 KEY CHARACTERISTICS OF HPAPI MANUFACTURING

3 MARKET ANALYSIS

3.1 INTRODUCTION

3.2 MARKET SEGMENTATION

3.3 FACTORS INFLUENCING MARKET

3.3.1 DRIVERS AND OPPORTUNITIES

3.3.1.1 Increasing incidence of chronic and age related diseases

3.3.1.2 Rapid growth in oncology market

3.3.1.3 Growing demand for Antibody Drug Conjugates (ADCs)

3.3.1.4 Technological advancements in HPAPI market

3.3.1.5 Growing CMOs (contract manufacturing organizations) market

3.3.2 RESTRAINTS AND THREATS

3.3.2.1 Requirement of large investment

3.3.2.2 Stringent safety and handling specifications associated with the production of

HPAPI

3.3.2.3 Stringent regulations

3.3.2.4 Alternative therapies to cure the cancer

3.4 PORTER'S FIVE FORCE ANALYSIS

3.4.1 THREAT OF NEW ENTRANTS

- 3.4.2 THREAT OF SUBSTITUTES
- 3.4.3 RIVALRY AMONG EXISTING COMPETITORS
- 3.4.4 BARGAINING POWER OF BUYERS
- 3.4.5 BARGAINING POWER OF SUPPLIERS
- 3.5 REGULATORY AFFAIRS
 - 3.5.1 U.S.
 - 3.5.2 EUROPE
 - 3.5.3 ASIA PACIFIC
 - 3.5.4 REST OF THE WORLD
- 3.6 MARKET SHARE ANALYSIS BY MAJOR PLAYERS
- 3.7 SUPPLY CHAIN ANALYSIS
- 3.8 SELECTED TOP SELLING HPAPI
- 3.9 RECENT HPAPI INVESTMENTS

4 HPAPI GLOBAL MARKET, BY CUSTOMER BASE

- 4.1 INTRODUCTION
- 4.2 INNOVATIVE HPAPI
- 4.3 GENERIC HPAPI

5 HPAPI GLOBAL MARKET, BY BUSINESS TYPE

- 5.1 INTRODUCTION
- 5.2 CAPTIVE HPAPI
- 5.3 MERCHANT HPAPI

6 HPAPI GLOBAL MARKET, BY MOLECULE TYPE

- 6.1 INTRODUCTION
- 6.2 SYNTHETIC HPAPIS
- 6.3 BIOTECH HPAPIS

7 HPAPI GLOBAL MARKET, BY APPLICATIONS

- 7.1 INTRODUCTION
- 7.2 CENTRAL NERVOUS SYSTEM DISORDERS
- 7.3 ONCOLOGY
- 7.4 HORMONAL DISORDERS
- 7.5 GLAUCOMA

- 7.6 INFECTIOUS DISEASES
- 7.7 METABOLIC DISORDERS
- 7.8 CARDIOVASCULAR
- 7.9 INFLAMMATION
- 7.10 OTHER THERAPEUTIC APPLICATIONS

8 REGIONAL MARKET ANALYSIS

- 8.1 INTRODUCTION
- 8.2 NORTH AMERICA
 - 8.2.1 U.S.
 - 8.2.2 OTHERS
- 8.3 EUROPE
 - 8.3.1 SWITZERLAND
 - 8.3.2 GERMANY
 - 8.3.3 U.K.
 - 8.3.4 OTHERS
- 8.4 ASIA PACIFIC
 - 8.4.1 INDIA
 - 8.4.2 CHINA
 - 8.4.3 JAPAN
 - 8.4.4 OTHERS
- 8.5 REST OF THE WORLD (ROW)
 - 8.5.1 BRAZIL
 - 8.5.2 REST OF LATIN AMERICA
 - 8.5.3 MIDDLE EAST & OTHERS

9 COMPETITIVE LANDSCAPE

- 9.1 INTRODUCTION

10. MAJOR COMPANIES

- 10.1 ALKERMES PLC
 - 10.1.1 OVERVIEW
 - 10.1.2 FINANCIALS
 - 10.1.3 SERVICE PORTFOLIO
 - 10.1.4 KEY DEVELOPMENTS
 - 10.1.5 BUSINESS STRATEGY

- 10.1.6 SWOT ANALYSIS
- 10.2 CAMBREX CORPORATION
 - 10.2.1 OVERVIEW
 - 10.2.2 FINANCIALS
 - 10.2.3 SERVICE PORTFOLIO
 - 10.2.4 KEY DEVELOPMENTS
 - 10.2.5 BUSINESS STRATEGY
 - 10.2.6 SWOT ANALYSIS
- 10.3 DISHMAN GROUP
 - 10.3.1 OVERVIEW
 - 10.3.2 FINANCIALS
 - 10.3.3 SERVICE PORTFOLIO
 - 10.3.4 KEY DEVELOPMENTS
 - 10.3.5 BUSINESS STRATEGY
 - 10.3.6 SWOT ANALYSIS
- 10.4 DR. REDDY'S LABORATORIES
 - 10.4.1 OVERVIEW
 - 10.4.2 FINANCIALS
 - 10.4.3 SERVICE PORTFOLIO
 - 10.4.4 KEY DEVELOPMENTS
 - 10.4.5 BUSINESS STRATEGY
 - 10.4.6 SWOT ANALYSIS
- 10.5 LONZA GROUP
 - 10.5.1 OVERVIEW
 - 10.5.2 FINANCIALS
 - 10.5.3 SERVICE PORTFOLIO
 - 10.5.4 KEY DEVELOPMENTS
 - 10.5.5 BUSINESS STRATEGY
 - 10.5.6 SWOT ANALYSIS
- 10.6 NOVASEP
 - 10.6.1 OVERVIEW
 - 10.6.2 FINANCIALS
 - 10.6.3 SERVICE PORTFOLIO
 - 10.6.4 KEY DEVELOPMENTS
 - 10.6.5 BUSINESS STRATEGY
 - 10.6.6 SWOT ANALYSIS
- 10.7 PATHEON N.V.(THERMOFISHER SCIENTIFIC)
 - 10.7.1 OVERVIEW
 - 10.7.2 FINANCIALS

- 10.7.3 SERVICE PORTFOLIO
- 10.7.4 KEY DEVELOPMENTS
- 10.7.5 BUSINESS STRATEGY
- 10.7.6 SWOT ANALYSIS
- 10.8 PFIZER INC.
 - 10.8.1 OVERVIEW
 - 10.8.2 FINANCIALS
 - 10.8.3 PRODUCT PORTFOLIO
 - 10.8.4 SERVICE PORTFOLIO
 - 10.8.5 KEY DEVELOPMENTS
 - 10.8.6 BUSINESS STRATEGY
 - 10.8.7 SWOT ANALYSIS
- 10.9 MERCK KGAA
 - 10.9.1 OVERVIEW
 - 10.9.2 FINANCIALS
 - 10.9.3 PRODUCT PORTFOLIO
 - 10.9.4 KEY DEVELOPMENTS
 - 10.9.5 BUSINESS STRATEGY
 - 10.9.6 SWOT ANALYSIS
- 10.10 TEVA PHARMACEUTICAL INDUSTRIES
 - 10.10.1 OVERVIEW
 - 10.10.2 FINANCIALS
 - 10.10.3 SERVICE PORTFOLIO
 - 10.10.4 KEY DEVELOPMENTS
 - 10.10.5 BUSINESS STRATEGY
 - 10.10.6 SWOT ANALYSIS

List Of Tables

LIST OF TABLES

Table 1 HPAPI GLOBAL MARKET REVENUE, BY REGION (2015-2023) (\$MN)

Table 2 HPAPI GLOBAL MARKET REVENUE, BY CUSTOMER BASE (2015-2023) (\$MN)

Table 3 INNOVATIVE HPAPI GLOBAL MARKET REVENUE, BY REGION (2015-2023) (\$MN)

Table 4 GENERIC HPAPI GLOBAL MARKET REVENUE, BY REGION (2015-2023) (\$MN)

Table 5 HPAPI GLOBAL MARKET REVENUE, BY BUSINESS TYPE (2015-2023) (\$MN)

Table 6 CAPTIVE HPAPI GLOBAL MARKET REVENUE, BY REGION (2015-2023) (\$MN)

Table 7 MERCHANT HPAPI GLOBAL MARKET REVENUE, BY REGION (2015-2023) (\$MN)

Table 8 HPAPI GLOBAL MARKET REVENUE, BY MOLECULE TYPE (2015-2023) (\$MN)

Table 9 SYNTHETIC HPAPI GLOBAL MARKET REVENUE, BY REGION (2015-2023) (\$MN)

Table 10 BIOTECH HPAPI GLOBAL MARKET REVENUE, BY REGION (2015-2023) (\$MN)

Table 11 HPAPI GLOBAL MARKET REVENUE, BY APPLICATIONS, (2015-2023) (\$MN)

Table 12 CENTRAL NERVOUS SYSTEMS HPAPI GLOBAL MARKET REVENUE, BY REGION, (2015-2023) (\$MN)

Table 13 ONCOLOGY HPAPI GLOBAL MARKET REVENUE, BY REGION, (2015-2023) (\$MN)

Table 14 HORMONAL DISORDERS HPAPI GLOBAL MARKET REVENUE, BY REGION, (2015-2023) (\$MN)

Table 15 GLAUCOMA HPAPI GLOBAL MARKET REVENUE, BY REGION, (2015-2023) (\$MN)

Table 16 INFECTIOUS DISEASES HPAPI GLOBAL MARKET REVENUE, BY REGION, (2015-2023) (\$MN)

Table 17 METABOLIC DISORDERS HPAPI GLOBAL MARKET REVENUE, BY REGION, (2015-2023) (\$MN)

Table 18 CARDIOVASCULAR HPAPI GLOBAL MARKET REVENUE, BY REGION, (2015-2023) (\$MN)

Table 19 INFLAMMATION HPAPI GLOBAL MARKET REVENUE, BY REGION,
(2015-2023) (\$MN)

Table 20 OTHER APPLICATIONS HPAPI GLOBAL MARKET REVENUE, BY REGION,
(2015-2023) (\$MN)

Table 21 NORTH AMERICAN HPAPI MARKET REVENUE, BY CUSTOMER BASE,
(2015-2023) (\$MN)

Table 22 NORTH AMERICAN HPAPI MARKET REVENUE, BY BUSINESS TYPE,
(2015-2023) (\$MN)

Table 23 NORTH AMERICAN HPAPI MARKET REVENUE, BY MOLECULE TYPE,
(2015-2023) (\$MN)

Table 24 NORTH AMERICAN HPAPI MARKET REVENUE, BY APPLICATIONS,
(2015-2023) (\$MN)

Table 25 EUROPEAN HPAPI MARKET REVENUE, BY CUSTOMER BASE,
(2015-2023) (\$MN)

Table 26 EUROPEAN HPAPI MARKET REVENUE, BY BUSINESS TYPE, (2015-2023)
(\$MN)

Table 27 EUROPEAN HPAPI MARKET REVENUE, BY MOLECULE TYPE,
(2015-2023) (\$MN)

Table 28 EUROPEAN HPAPI MARKET REVENUE, BY APPLICATIONS, (2015-2023)
(\$MN)

Table 29 ASIA PACIFIC HPAPI MARKET REVENUE, BY CUSTOMER BASE,
(2015-2023) (\$MN)

Table 30 ASIA PACIFIC HPAPI MARKET REVENUE, BY BUSINESS TYPE,
(2015-2023) (\$MN)

Table 31 ASIA PACIFIC HPAPI MARKET REVENUE, BY MOLECULE TYPE,
(2015-2023) (\$MN)

Table 32 ASIA PACIFIC HPAPI MARKET REVENUE, BY APPLICATIONS (2015-2023)
(\$MN)

Table 33 ROW HPAPI MARKET REVENUE, BY CUSTOMER BASE, (2015-2023)
(\$MN)

Table 34 ROW HPAPI MARKET REVENUE, BY BUSINESS TYPE, (2015-2023) (\$MN)

Table 35 ROW HPAPI MARKET REVENUE, BY MOLECULE TYPE, (2015-2023)
(\$MN)

Table 36 ROW HPAPI MARKET REVENUE, BY APPLICATIONS (2015-2023) (\$MN)

Table 37 EXPANSIONS, AGREEMENTS, ACQUISITIONS, APPROVALS AND OTHER
DEVELOPMENTS (2015-2017)

Table 38 ALKERMES PLC: TOTAL REVENUE AND R&D EXPENSES, (2015-2017)
(\$MN)

Table 39 ALKERMES PLC: TOTAL REVENUE, BY SEGMENTS, (2015-2017) (\$MN)

Table 40 ALKERMES PLC: TOTAL REVENUE, BY SUB-SEGMENTS, (2015-2017) (\$MN)

Table 41 ALKERMES PLC: TOTAL REVENUE, BY GEOGRAPHY, (2015-2017) (\$MN)

Table 42 CAMBREX CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2015-2017) (\$MN)

Table 43 CAMBREX CORPORATION: TOTAL REVENUE, BY GEOGRAPHY, (2015-2017) (\$MN)

Table 44 DISHMAN GROUP: TOTAL REVENUE AND R&D EXPENSES, (2014-2016) (\$MN)

Table 45 DISHMAN GROUP: TOTAL REVENUE, BY SEGMENTS, (2014-2016) (\$MN)

Table 46 DR. REDDY'S LABORATORIES: TOTAL REVENUE AND R&D EXPENSES, (2014-2016) (\$MN)

Table 47 DR. REDDY'S LABORATORIES: TOTAL REVENUE, BY SEGMENTS, (2014-2016) (\$MN)

Table 48 DR. REDDY'S LABORATORIES: TOTAL REVENUE, BY GEOGRAPHY, (2014-2016) (\$MN)

Table 49 LONZA GROUP: TOTAL REVENUE AND R&D EXPENSES (2015-2017) (\$MN)

Table 50 LONZA GROUP: TOTAL REVENUE, BY SEGMENT, (2015-2017) (\$MN)

Table 51 LONZA GROUP: TOTAL REVENUE, BY GEOGRAPHY (2015-2017) (\$MN)

Table 52 PATHEON N.V.: TOTAL REVENUE AND R&D EXPENSES (2015-2017) (\$MN)

Table 53 PATHEON N.V.: TOTAL REVENUE, BY SEGMENT, (2015-2017) (\$MN)

Table 54 PATHEON N.V.: TOTAL REVENUE, BY GEOGRAPHY (2015-2017) (\$MN)

Table 55 PFIZER INC: TOTAL REVENUE AND R&D EXPENSES, (2015-2017) (\$MN)

Table 56 PFIZER INC: TOTAL REVENUE, BY SEGMENTS, (2015-2017) (\$MN)

Table 57 PFIZER INC: TOTAL REVENUE, BY GEOGRAPHY, (2015-2017) (\$MN)

Table 58 MERCK KGAA: TOTAL REVENUE AND R&D EXPENSES, (2015-2017) (\$MN)

Table 59 MERCK KGAA: TOTAL REVENUE, BY SEGMENTS, (2015-2017) (\$MN)

Table 60 MERCK KGAA: TOTAL REVENUE, BY GEOGRAPHY, (2015-2017) (\$MN)

Table 61 TEVA PHARMACEUTICAL INDUSTRIES: TOTAL REVENUE AND R&D EXPENSES, (2015-2017) (\$MN)

Table 62 TEVA PHARMACEUTICAL INDUSTRIES: TOTAL REVENUE, BY SEGMENTS, (2015-2017) (\$MN)

Table 63 TEVA PHARMACEUTICAL INDUSTRIES: TOTAL REVENUE, BY GEOGRAPHY, (2015-2017) (\$MN)

List Of Figures

LIST OF FIGURES

Figure 1 HPAPI GLOBAL MARKET SHARE AND REVENUE, BY REGION (2015-2023)

Figure 2 RESEARCH METHODOLOGY: HPAPI GLOBAL MARKET

Figure 3 HPAPI GLOBAL MARKET: TOP-DOWN AND BOTTOM-UP APPROACH

Figure 4 HPAPI GLOBAL MARKET: FORECASTING MODEL

Figure 5 HPAPI GLOBAL MARKET: MARKET BREAKDOWN & DATA
TRIANGULATION

Figure 6 HPAPI GLOBAL MARKET SEGMENTATION

Figure 7 MARKET DYNAMICS

Figure 8 HPAPI GLOBAL MARKET: PORTER'S ANALYSIS

Figure 9 HPAPI GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS 2016 (%)

Figure 10 HPAPI MARKET: SUPPLY CHAIN ANALYSIS

Figure 11 HPAPI GLOBAL MARKET SHARE, BY CUSTOMER BASE (2016 V/S 2023)
(%)

Figure 12 HPAPI GLOBAL MARKET REVENUE, BY BUSINESS TYPE (2016 V/S
2023) (\$ MN)

Figure 13 HPAPI GLOBAL MARKET REVENUE, BY MOLECULE TYPE (2016 V/S
2023) (\$ MN)

Figure 14 HPAPI GLOBAL MARKET SHARE, BY APPLICATIONS (2016) (%)

Figure 15 HPAPI GLOBAL MARKET SHARE AND REVENUE, BY REGION
(2016-2023) (\$MN)

Figure 16 NORTH AMERICAN HPAPI MARKET REVENUE, BY CUSTOMER BASE,
BUSINESS TYPE & MOLECULE TYPE (2016 V/S 2023) (\$MN)

Figure 17 NORTH AMERICAN HPAPI MARKET SHARE, BY APPLICATIONS (2016
V/S 2023) (%)

Figure 18 UNITED STATES HPAPI MARKET REVENUE, BY CUSTOMER BASE,
BUSINESS TYPE & MOLECULE TYPE (2016 V/S 2023) (\$MN)

Figure 19 UNITED STATES HPAPI MARKET SHARE, BY APPLICATIONS (2016 V/S
2023) (%)

Figure 20 OTHER NORTH AMERICAN REGIONS HPAPI MARKET REVENUE, BY
CUSTOMER BASE, BUSINESS TYPE & MOLECULE TYPE (2016 V/S 2023) (\$MN)

Figure 21 OTHER NORTH AMERICAN REGIONS HPAPI MARKET SHARE, BY
APPLICATIONS (2016 V/S 2023) (%)

Figure 22 EUROPEAN HPAPI MARKET REVENUE, BY CUSTOMER BASE,
BUSINESS TYPE & MOLECULE TYPE (2016 V/S 2023) (\$MN)

Figure 23 EUROPEAN HPAPI MARKET SHARE, BY APPLICATIONS (2016 V/S 2023)

(\$MN)

Figure 24 SWITZERLAND HPAPI MARKET REVENUE, BY CUSTOMER BASE, BUSINESS TYPE & MOLECULE TYPE (2016 V/S 2023) (\$MN)

Figure 25 SWITZERLAND HPAPI MARKET SHARE, BY APPLICATIONS (2016 V/S 2023) (%)

Figure 26 GERMANY HPAPI MARKET REVENUE, BY CUSTOMER BASE, BUSINESS TYPE & MOLECULE TYPE (2016 V/S 2023) (\$MN)

Figure 27 GERMANY HPAPI MARKET SHARE, BY APPLICATIONS (2016 V/S 2023) (%)

Figure 28 U.K. HPAPI MARKET REVENUE, BY CUSTOMER BASE, BUSINESS TYPE & MOLECULE TYPE (2016 V/S 2023) (\$MN)

Figure 29 U.K. HPAPI MARKET SHARE, BY APPLICATIONS (2016 V/S 2023) (%)

Figure 30 OTHER EUROPEAN REGIONS HPAPI MARKET REVENUE, BY CUSTOMER BASE, BUSINESS TYPE & MOLECULE TYPE (2016 V/S 2023) (\$MN)

Figure 31 OTHER EUROPEAN REGIONS HPAPI MARKET SHARE, BY APPLICATIONS (2016 V/S 2023) (%)

Figure 32 ASIA PACIFIC HPAPI MARKET REVENUE, BY CUSTOMER BASE, BUSINESS TYPE & MOLECULE TYPE (2016 V/S 2023) (\$MN)

Figure 33 ASIA PACIFIC HPAPI MARKET SHARE, BY APPLICATIONS (2016 V/S 2023) (%)

Figure 34 INDIA HPAPI MARKET REVENUE, BY CUSTOMER BASE, BUSINESS TYPE & MOLECULE TYPE (2016 V/S 2023) (\$MN)

Figure 35 INDIA HPAPI MARKET SHARE, BY APPLICATIONS (2016 V/S 2023) (%)

Figure 36 CHINA HPAPI MARKET REVENUE, BY CUSTOMER BASE, BUSINESS TYPE & MOLECULE TYPE (2016 V/S 2023) (\$MN)

Figure 37 CHINA HPAPI MARKET SHARE, BY APPLICATIONS (2016 V/S 2023) (%)

Figure 38 JAPAN HPAPI MARKET REVENUE, BY CUSTOMER BASE, BUSINESS TYPE & MOLECULE TYPE (2016 V/S 2023) (\$MN)

Figure 39 JAPAN HPAPI MARKET SHARE, BY APPLICATIONS (2016 V/S 2023) (%)

Figure 40 OTHER ASIA PACIFIC REGIONS HPAPI MARKET REVENUE, BY CUSTOMER BASE, BUSINESS TYPE & MOLECULE TYPE (2016 V/S 2023) (%)

Figure 41 OTHER ASIA PACIFIC REGIONS HPAPI SHARE, BY APPLICATIONS (2016 V/S 2023) (%)

Figure 42 ROW HPAPI MARKET REVENUE, BY CUSTOMER BASE, BUSINESS TYPE & MOLECULE TYPE (2016 V/S 2023) (\$MN)

Figure 43 ROW HPAPI MARKET SHARE BY APPLICATIONS (2016 V/S 2023) (%)

Figure 44 BRAZIL HPAPI MARKET REVENUE, BY CUSTOMER BASE, BUSINESS TYPE & MOLECULE TYPE (2016 V/S 2023) (\$MN)

Figure 45 BRAZIL HPAPI MARKET SHARE, BY APPLICATIONS (2016 V/S 2023) (%)

Figure 46 REST OF LATIN AMERICA HPAPI MARKET REVENUE, BY CUSTOMER BASE, BUSINESS TYPE & MOLECULE TYPE (2016 V/S 2023) (\$MN)

Figure 47 REST OF LATIN AMERICA HPAPI MARKET REVENUE, BY APPLICATIONS (2016 V/S 2023) (%)

Figure 48 MIDDLE EAST & OTHERS HPAPI MARKET REVENUE, BY CUSTOMER BASE, BUSINESS TYPE & MOLECULE TYPE (2016 V/S 2023) (\$MN)

Figure 49 MIDDLE EAST & OTHERS HPAPI MARKET SHARE, BY APPLICATIONS (2016 V/S 2023) (%)

Figure 50 KEY GROWTH STRATEGIES, (2015 – 2017)

Figure 51 SWOT: ALKERMES PLC

Figure 52 SWOT: CAMBREX CORPORATION

Figure 53 SWOT: DISHMAN GROUP

Figure 54 SWOT: DR. REDDY'S LABORATORIES

Figure 55 SWOT: LONZA GROUP

Figure 56 SWOT: NOVASEP

Figure 57 SWOT: PATHEON N.V.

Figure 58 SWOT: PFIZER INC.

Figure 59 SWOT: MERCK KGAA

Figure 60 SWOT: TEVA PHARMACEUTICAL INDUSTRIES

I would like to order

Product name: High Potency Active Pharmaceutical Ingredients (HPAPI) Global Market – Forecast To 2023

Product link: <https://marketpublishers.com/r/H3CED6D8265EN.html>

Price: US\$ 4,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H3CED6D8265EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

